U.S. federal health officials said patients should take antiretroviral meds as soon as they are diagnosed instead of waiting to start therapy, potentially opening the door for increased sales of the drugs.
India's Aurobindo Pharma has submitted an abbreviated new drug application (ANDA) to the FDA for the treatment of HIV as part of the country's pharmaceutical industry's efforts to ramp up production of drugs to treat HIV/AIDS.
After getting started 9 years ago with backing from angel investors, Calimmune just landed a $15 million B round, positioning the biotech to move into the clinic with a gene therapy designed to durably stymie the lethal HIV with one treatment.
A struggling GlaxoSmithKline has set up an economy-sized research spinout with the University of North Carolina at Chapel Hill that's short on cash and long--very, very long--on its promise to hunt for a cure for HIV.
As the industry turns its attention to low-cost, easy-to-use diagnostics for developing countries, researchers at Florida Atlantic University are developing a biosensing tool that uses a smartphone and a paper microchip to screen for diseases such as HIV.
China's TaiMed Biologics has won the FDA's breakthrough drug title for its HIV therapy, ibalizumab (TMB-355), making it apparently the first Chinese med to get onto the list.
In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
The FDA has approved a triple test from Roche to simultaneously detect HIV, hepatitis C and hepatitis B in donated blood and blood products. It's the first test approved by the agency to simultaneously test for all three of these blood-borne diseases and is expected to reduce the necessary sample volume and the testing turnaround time.
Argos Therapeutics' HIV treatment failed to meet its main goal in a midstage trial, raising concerns about the company's platform technology and sending its shares spiraling downward.
Last year, India's Cipla forked over $500 million to get complete ownership of South Africa's Cipla Medpro. A new contract from the South African government for antiretroviral drugs sheds some light on the potential motivation for more than doubling its original offer to get the whole company.